All News

26 March 2012

Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 AntibodyAntibodies

26 March 2012

Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development ProgramsAntibodies

26 March 2012

Amgen’s PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b StudyAntibodies

24 March 2012

BT-062 demonstrates rapid and complete tumor eradication in preclinical studiesAntibodies

24 March 2012

Roche’s Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusionAntibodies

24 March 2012

Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for TrastuzumabAntibodies

24 March 2012

Daiichi Sankyo Files for Approval in Japan to Market AMG 162 (denosumab), a Treatment for OsteoporosisAntibodies

21 March 2012

Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 AntibodyAntibodies

19 March 2012

Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCLAntibodies

15 March 2012

Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis SuppurativaAntibodies

13 March 2012

biOasis’ BT2111-Herceptin(R) Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity AssayAntibodies

9 March 2012

Peregrine Reports Data From Phase II Front-Line Lung Cancer TrialAntibodies

9 March 2012

Study Establishes XOMA’s XMetA as the First Allosteric Insulin Receptor-Activating Antibody to Improve Glycemic Control In VivoAntibodies

6 March 2012

MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis TrialAntibodies

5 March 2012

Anthera Pharmaceuticals Completes Interim Analysis of PEARL-SC Clinical Trial with BlisibimodAntibodies

3 March 2012

Recruitment of patients completed in phase II study with BI-204Antibodies

2 March 2012

Genentech’s ACTEMRA Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab MonotherapyAntibodies

27 February 2012

FDA approves protocol amendment needed to conduct the final analysis of the pivotal RENCAREX Phase III trialAntibodies

22 February 2012

UCB announces start of C-EARLY™ study for Cimzia (certolizumab pegol) in rheumatoid arthritisAntibodies

20 February 2012

Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional TherapyAntibodies

20 February 2012

Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-EyeAntibodies

9 February 2012

In-vivo proof of concept achieved by targeting of IL1RAP on human tumorAntibodies

8 February 2012

Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee MeetingAntibodies

8 February 2012

ARGEN-X ADVANCES A THIRD THERAPEUTIC ANTIBODY PROGRAM INTO PRECLINICAL DEVELOPMENTAntibodies

7 February 2012

FDA Grants Genentech’s Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast CancerAntibodies

2 February 2012

Compugen Cancer Target Results Demonstrate Significant Potential for Cancer ImmunotherapyAntibodies

30 January 2012

VGX-100 Identified as Potential New Therapy for Improving Corneal Graft SurvivalAntibodies

30 January 2012

biOasis Advances its Herceptin(R) BT2111 ProgramAntibodies

29 January 2012

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish SourceAntibodies

29 January 2012

Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS in Front-line Mature T-Cell LymphomasAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

CD40 Agonists & CD40/L Antagonists Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

CD73 Inhibitor Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

PSMA-Targeted Therapy Pipeline Review

TSLP Pipeline Review